CYP3A4 overexpression enhances the cytotoxicity of the antitumor triazoloacridinone derivative C-1305 in CHO cells

CYP3A4 Mediates Growth of Estrogen Receptor-positive Breast Cancer Cells in Part by Inducing Nuclear Translocation of Phospho-Stat3 through Biosynthesis of (±)-14,15-Epoxyeicosatrienoic Acid (EET)

(2011) Ranjana Mitra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Flavin monooxygenases, FMO1 and FMO3, not cytochrome P450 isoenzymes, contribute to metabolism of anti-tumour triazoloacridinone, C-1305, in liver microsomes and HepG2 cells

(2011) Barbara Fedejko-Kap et al.   XENOBIOTICA

Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints

(2010) Michal Sabisz et al.   BIOCHEMICAL PHARMACOLOGY

Distinct Roles of Cytochrome P450 Reductase in Mitomycin c Redox Cycling and Cytotoxicity

(2010) Y. Wang et al.   MOLECULAR CANCER THERAPEUTICS

The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells

(2009) Jitka Poljaková et al.   BIOCHEMICAL PHARMACOLOGY

Cell Lines: A Tool for In Vitro Drug Metabolism Studies

(2008) M. Gomez-Lechon et al.   CURRENT DRUG METABOLISM

Cytochrome P450 ω-hydroxylase inhibition reduces cardiomyocyte apoptosis via activation of ERK1/2 signaling in rat myocardial ischemia-reperfusion

(2008) Xiaojun Lv et al.   EUROPEAN JOURNAL OF PHARMACOLOGY